eShowcase: Laboratory and Clinical Study Status
Secure Web-based Test Article Submissions and Study Tracking Availale
Secure Web-based Test Article Submissions and Study Tracking Available
BioReliance (Rockville, MD), a contract services organization, announces a Web-based proprietary software system called iNet. iNet allows customers to submit test article details via controlled and secure Internet access. Clients can then view the status of current and past studies, keep informed of expected completion dates, download reports, and share information with colleagues to view testing status.
iNet from BioReliance
Components of iNet include projected lab initiation and report completion dates, which help to facilitate planning efforts. Electronic templates are also included for sample submissions to manage timelines and simplify processes. The product is compliant with 21 CFR Part 11 for user authentication. Data exchange is protected by Secured Sockets Layer certificates from VeriSign.
BioReliance, (301) 610-2544, www.bioreliance.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
